Advanced in Alstrom Syndrome

Dr. Andrea M. Haqq

Pediatrics | Endocrinology
2100 Erwin Rd, 
Durham, NC 
Advanced in Alstrom Syndrome
2100 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrea Haqq is a Pediatrics specialist and an Endocrinologist in Durham, North Carolina. Dr. Haqq is rated as an Advanced provider by MediFind in the treatment of Alstrom Syndrome. Her top areas of expertise are Bardet-Biedl Syndrome, Prader-Willi Syndrome, Obesity, Sleeve Gastrectomy, and Islet Cell Transplantation.

Her clinical research consists of co-authoring 86 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Alstrom Syndrome.

Specialties
Pediatrics
Endocrinology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2100 Erwin Rd, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2/Phase 3
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 3
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Enrollment Status: Completed
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Enrollment Status: Completed
Publish Date: November 15, 2022
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Involving Variants in Hypothalamic Genes Upstream or Downstream From the Melanocortin-4 Receptor (MC4R)
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Involving Variants in Hypothalamic Genes Upstream or Downstream From the Melanocortin-4 Receptor (MC4R)
Enrollment Status: Completed
Publish Date: May 04, 2021
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: March 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

86 Total Publications

Early-Onset of Obesity Model: Impact of Early-Onset Obesity on Comorbidity Risk and Life Expectancy.
Early-Onset of Obesity Model: Impact of Early-Onset Obesity on Comorbidity Risk and Life Expectancy.
Journal: Obesity facts
Published: May 08, 2025
Similar Doctors
Experienced in Alstrom Syndrome
Dr. Ermal Aliu
Pediatrics | Medical Genetics
Experienced in Alstrom Syndrome
Dr. Ermal Aliu
Pediatrics | Medical Genetics

Duke Health Integrated Practice Inc

4709 Creekstone Dr, Suite 300, 
Durham, NC 
 (10.0 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances

Ermal Aliu is a Pediatrics specialist and a Medical Genetics provider in Durham, North Carolina. Dr. Aliu is rated as an Advanced provider by MediFind in the treatment of Alstrom Syndrome. His top areas of expertise are Phenylketonuria (PKU), Learman Syndrome, Microcephaly, and Symphalangism Distal.

Laura K. Ferris
Experienced in Alstrom Syndrome
Dr. Laura K. Ferris
Dermatology | Pediatrics | General Practice
Experienced in Alstrom Syndrome
Dr. Laura K. Ferris
Dermatology | Pediatrics | General Practice

University Of North Carolina At Chapel Hill

410 Market St, Suite 400a, 
Chapel Hill, NC 
 (11.4 miles away)
984-974-3900
Languages Spoken:
English
See accepted insurances

Laura Ferris is a Dermatologist and an Internal Medicine provider in Chapel Hill, North Carolina. Dr. Ferris is rated as a Distinguished provider by MediFind in the treatment of Alstrom Syndrome. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Melanoma, and Familial Atypical Multiple Mole Melanoma Syndrome.

Experienced in Alstrom Syndrome
Dr. Chad Haldeman
Medical Genetics | Pediatrics
Experienced in Alstrom Syndrome
Dr. Chad Haldeman
Medical Genetics | Pediatrics

The Moses H Cone Memorial Hospital Operating Corporation

1200 N Elm St, 
Greensboro, NC 
 (48.1 miles away)
336-574-7771
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chad Haldeman is a Medical Genetics specialist and a Pediatrics provider in Greensboro, North Carolina. Dr. Haldeman is rated as an Advanced provider by MediFind in the treatment of Alstrom Syndrome. His top areas of expertise are Fabry Disease, Megalencephalic Leukoencephalopathy with Subcortical Cysts, Multiple Sulfatase Deficiency, and Pompe Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haqq's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile